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Abstract  The  Schizophrenia  Objective  Functioning  Instrument  (SOFI)  is  an  interviewer-
administered  scale  designed  to  objectively  assess  the  actual  level  of  patient  functioning  and  to
measure community  functioning  related  to  cognitive  impairment  and  psychopathology.  The  aim
was to  examine  the  psychometric  properties  of  the  Spanish  version  of  the  SOFI  (Sp-SOFI)  in  a
sample of  155  Spanish  outpatients  with  schizophrenia  disorder.  The  instruments  applied  were  Sp-
SOFI, Positive  and  Negative  Syndrome  Scale  (PANSS),  Clinical  Global  Impression-Schizophrenia
Scale (CGI-SCH),  Personal  and  Social  Performance  Scale  (PSP),  and  Global  Assessment  of  Func-
tioning (GAF).  The  discrimination  indexes  of  the  Sp-SOFI  items  range  from  .21  to  .77.  Exploratory
factor analysis  showed  an  essentially  one-dimensional  structure.  Cronbach’s  alpha  was  .93.
Test-retest  reliability  for  the  Sp-SOFI  total  score  was  .87  (p  <  .001).  The  canonical  correlation
between SP-SOFI  domains  and  PSP  dimensions  was  .83.  The  multiple  correlation  coefﬁcient
between Sp-SOFI  domains  and  GAF  score  was  .84.  Sp-SOFI  scores  were  signiﬁcantly  different∗ Corresponding author: Department of Psychiatry, School of Medicine, University of Oviedo, Julián Clavería 6-3◦, 33006 Oviedo, Spain.
E-mail address: albert@uniovi.es (M.P. García-Portilla).
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between  high  and  low  scores  on  the  PANSS  scales  (p  <  .001).  Sp-SOFI  measures  discriminated
among patients  with  doubtful,  mild,  moderate,  and  severe  schizophrenia  disorder  according
to CGI-SCH  scales  (p  <  .001).  New  evidence  about  the  validity  of  the  SOFI  was  provided.  The
Sp-SOFI is  a  reliable  and  valid  tool  for  using  in  clinical  practice.
© 2015  Asociación  Espan˜ola  de  Psicología  Conductual.  Published  by  Elsevier
España,  S.L.U.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Propiedades  psicométricas  de  la  versión  en  espan˜ol  del  Instrumento  de
Funcionamiento  Objetivo  para  la  Esquizofrenia  (Sp-SOFI)
Resumen  El  Instrumento  de  Funcionamiento  Objetivo  para  la  Esquizofrenia  (SOFI)  es  una
entrevista para  evaluar  el  nivel  de  funcionamiento  comunitario  en  relación  con  el  dan˜o  cognitivo
y los  síntomas  psicopatológicos.  El  objetivo  del  estudio  consistió  en  examinar  las  propiedades
psicométricas  de  la  versión  espan˜ola  de  la  SOFI  (Sp-SOFI)  en  una  muestra  de  155  pacientes
ambulatorios  con  esquizofrenia.  Los  índices  de  discriminación  de  la  Sp-SOFI  oscilaron  entre
0,21 y  0,77.  El  análisis  factorial  exploratorio  mostró  una  estructura  esencialmente  unidimen-
sional. El  alfa  de  Cronbach  fue  0,93.  El  coeﬁciente  de  ﬁabilidad  test-retest  fue  0,87  (p  <  0,001).
La correlación  canónica  entre  la  Sp-SOFI  y  la  Escala  de  Funcionamiento  Personal  y  Social  (PSP)
fue 0,83.  El  coeﬁciente  de  correlación  múltiple  entre  la  Sp-SOFI  y  la  Escala  de  Evaluación  de
la Actividad  Global  (EEAG)  fue  0,44.  Las  puntuaciones  en  la  Sp-SOFI  fueron  signiﬁcativamente
diferentes  entre  los  pacientes  con  puntuaciones  altas  y  bajas  en  la  Escala  del  Síndrome  Pos-
itivo y  Negativo  (PANSS)  (p  <  0,001).  La  Sp-SOFI  discriminó  entre  pacientes  con  trastorno  de
esquizofrenia  dudoso,  leve,  moderado  y  grave  de  acuerdo  con  la  Escala  de  Impresión  Clínica
Global de  Esquizofrenia  (CGI-SCH)  (p  <  0,001).  La  Sp-SOFI  es  un  instrumento  ﬁable  y  válido  para
la práctica  clínica.
©  2015  Asociación  Espan˜ola  de  Psicología  Conductual.  Publicado  por  Elsevier
España, S.L.U.  Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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fSchizophrenia  is  associated  with  substantial  impairments
in  functional  outcomes,  including  social  and  occupational
functioning,  independent  living,  and  the  ability  to  per-
form  activities  of  daily  living  (Green,  Kern,  Braft,  &  Mints,
2000).  Additionally,  several  studies  have  shown  that  cogni-
tive  functions  are  impaired  in  patients  with  schizophrenia,
and  these  impairments  also  have  a  real  impact  on  the  daily
functioning  of  patients  with  this  disorder  (García-Portilla
et  al.,  2014;  Gavilán  &  García-Albea,  2014;  Menéndez-
Miranda  et  al.,  2015).  They  include  signiﬁcant  deﬁcits  in
memory,  attention,  problem  solving,  processing  speed,  and
social  cognition,  which  have  been  shown  to  be  associated
with  several  of  the  aforementioned  functional  impairments
(Keefe  et  al.,  2013).  This  association  between  cognition  and
outcome  is  robust  and  has  been  replicated  and  extended  in
many  countries,  using  many  different  types  of  assessments,
in  different  patient  groups  across  phase  of  illness  (Green
&  Harvey,  2014).  The  early  detection  of  these  matters  is  a
challenge,  particularly  with  respect  to  orientation  of  treat-
ment  (Gómez-Benito,  Guilera,  Pino,  Tabarés-Seisdedos,  &
Marínez-Arán,  2014).  One  of  the  greatest  difﬁculties  in  eval-
uating  this  issue  is  the  borderline  between  negative  and
cognitive  dimensions.  It  is  generally  accepted  that  these
two  dimensions  present  similar  characteristics  with  respect
to  prevalence,  difﬁculty  of  assessment,  progression,  progno-
stic  implications,  and  lack  of  effective  treatments.  However,
f
F
at  is  also  accepted  that  they  constitute  two  dimensions  that
re  independent  but  interrelated  (García-Portilla  &  Bobes,
013;  García-Portilla  et  al.,  2015).
The  Schizophrenia  Objective  Functioning  Instrument
SOFI)  was  developed  to  measure  changes  in  functional
utcomes  due  to  patient  psychopathology  and  cognitive
mpairment.  From  an  initial  meeting  of  experts  four
omains  emerged  as  most  relevant  to  a  functional  outcome
easure  in  schizophrenia:  1)  living  situation  (stability,
tructure/supervision,  independence);  2)  instrumental
ctivities  of  daily  living  (ﬁnancial  management,  trans-
ortation,  medication,  treatment,  housework/childcare,
elf-care,  shopping,  food/cooking,  planning  and  leisure
ctivities);  3)  productive  activities  (work,  other  vocational
riented  activities,  treatment-related  activities,  education,
omemaking/childcare);  and  4)  social  functioning  (social
ctivity  and  social  support)  (Kleinman  et  al.,  2009).  Existing
easures  were  reviewed  to  identify  relevant  items.  One
f  them  was  the  WHO-DAS-II  (Chisolm,  Abrams,  McArdle,
ilson,  &  Doyle,  2005),  which  is  directly  linked  at  the  level
f  the  concepts  to  the  WHO’s  International  Classiﬁcation
f  Functioning,  Disability  and  Health  (ICF).  This  provides  a
ramework  for  understanding  the  impact  of  environmental
actors  on  functioning  when  a  person  has  a  health  condition.
unctioning  and  disability  is  increasingly  being  taken  into
ccount  in  assessing  the  impact  of  schizophrenia  on  the
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ndividual,  as  well  as  the  effectiveness  of  treatments.
ifﬁculties  with  everyday  activities  and  low  health-related
uality  of  life  have  consistently  been  reported  as  being
elated  to  schizophrenia.  There  is  also  evidence  that  the
evel  of  impairment  in  individuals  with  schizophrenia  is
losely  linked  to  the  support  provided  by  different  aspects
f  the  environment,  not  only  the  family  and  the  community,
ut  also  social  services,  systems,  and  policies.  The  ICF  offers
 common  framework  for  collecting  data  on  functioning  and
isability  of  persons  living  with  schizophrenia  (ICF  Research
ranch,  2015).
The  objective  of  developing  the  SOFI  was  to  create  a
unctional  outcome  measure  that  could  be  used  in  clinical
rials,  psychological  treatments  and  other  clinical  stud-
es  evaluating  interventions  for  cognitive  impairment  and
sychopathology  in  schizophrenia  (Kleinman  et  al.,  2009).
his  need  is  strengthened  by  the  fact  that  The  World
ealth  Organization  Comprehensive  Mental  Health  Action
lan  2013--2020  proposes  ‘‘to  strengthen  information  sys-
ems,  evidence  and  research  for  mental  health’’  including
‘data  about  levels  of  disability,  overall  functioning  and
uality  of  life’’  (World  Health  Organization,  WHO,  2013).
Scientiﬁc  societies  such  as  American  Psychological  Asso-
iation  (APA)  or  European  Federation  of  Psychologists’
ssociations  (EFPA)  make  a  strong  cause  for  intervention
or  patients  with  schizophrenia  (European  Federation  of  Psy-
hologists’  Associations,  EFPA,  2014).  Psychologists  can  help
eople  with  schizophrenia  cope  with  the  difﬁcult  effects  of
he  disease,  including  challenges  related  to  self-care,  work,
chool  and  relationships  (American  Psychological  Associa-
ion,  APA,  2015).  Also,  the  European  Medicines  Agency,  EMEA
2005)  highlight  the  importance  of  providing  clinicians  with
dequate,  valid,  and  reliable  instruments  to  measure  other
utcomes  beyond  symptoms,  in  addition  to  functioning  and
uality  of  life.
For  all  this,  we  decided  to  conduct  this  study  in  order
o  validate  the  Spanish  version  of  the  SOFI  scale  (Sp-SOFI),
panish  being  the  third  most  commonly  spoken  language  in
he  world.  To  our  knowledge,  there  is  no  other  empirical
alidation  addressing  the  SOFI.  The  aims  of  this  study  were
o  translate  and  culturally  adapt  the  SOFI  and  examine  its
sychometric  properties  in  a  sample  of  Spanish  outpatients
ith  schizophrenia  under  standard  treatment.
ethod
his  instrumental  study  was  carried  out  using  an  instru-
ental,  longitudinal  design  (Carretero-Dios  &  Pérez,  2007;
ontero  &  León,  2007).  The  data  come  from  a  naturalis-
ic,  6-month  follow-up  validation  study  conducted  at  ﬁve
ites  located  in  ﬁve  different  cities  in  Spain.  It  was  approved
y  the  Clinical  Research  Ethics  Committee  of  the  lead  site
Hospital  Universitario  Central  de  Asturias,  Oviedo)  and  per-
ormed  in  accordance  with  the  1975  Declaration  of  Helsinki
nd  its  subsequent  revisions  (World  Medical  Association,
000).  Written  informed  consent  was  obtained  from  all  sub-
ects  prior  to  enrollment.articipants
he  study  sample  comprised  a  total  of  155  outpatients  with
chizophrenia.  Eligibility  criteria  for  inclusion  in  the  study
P
u
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ere:  age  between  18  and  65  years  (either  sex),  diagnosis  of
chizophrenia  (psychiatric  diagnosis  was  made  by  qualiﬁed
sychiatrists  using  ICD-10  criteria),  on  stable  maintenance
reatment,  and  written  informed  consent  to  participate  in
he  study.  Stability  was  deﬁned  as  patients  who  did  not
equire  any  change  in  their  current  pharmacological  treat-
ent  during  the  last  three  months.  The  same  criterion  was
pplied  during  the  follow  up.
Patients  with  intellectual  developmental  disorder,
cquired  brain  injury,  or  who  refused  to  participate  in  the
tudy  were  excluded.
nstruments  and  study  procedures
or  each  patient,  demographic  data  and  clinical  information
egarding  diagnosis,  medication,  and  drug  use  was  obtained.
everity  of  the  illness  and  the  level  of  functioning  were
ssessed.  All  testing  was  performed  by  the  same  clinician
t  baseline  and  6-month  follow-up.
Schizophrenia  Objective  Functioning  Instrument  (SOFI).
he  Schizophrenia  Objective  Functioning  Instrument  (SOFI)
s  an  interviewer-administered  scale  designed  to  objectively
ssess  the  actual  level  of  patient  functioning.  It  is  orga-
ized  into  four  domains:  1)  living  situation,  2)  instrumental
ctivities  of  daily  living,  3)  productive  activities,  and  4)
ocial  functioning  (Kleinman  et  al.,  2009).  Each  domain  is
ated  on  a global  score  of  0  to  100,  with  anchors  pro-
ided  for  each  10  point  level.  Higher  scores  indicate  better
unctioning.  Prior  to  completing  the  global  rating,  several
imensions  are  evaluated  for  each  domain  using  a  semi-
tructured  interview  format  with  patients  or  informants,  and
ncluding  any  additional  information.  In  addition,  an  over-
ll  global  score  is  calculated  by  taking  the  mean  of  the  four
omain  global  scores.  The  SOFI  was  translated  following  the
ules  of  the  International  Test  Commission  (Mun˜iz,  Elosua,  &
ambleton,  2013).  The  original  instrument  was  ﬁrst  trans-
ated  into  Spanish  by  three  independent  groups,  each  one
omposed  of  three  researchers  (psychologists  and  psychia-
rists)  who  were  ﬂuent  in  English.  Each  group  agreed  on  a
reliminary  version.  Then,  the  coordinators  of  each  group
pproved  the  ﬁnal  version.  Finally,  the  Spanish  version  was
ack-translated  by  a clinical  psychologist.  The  Spanish  ver-
ion  was  then  pilot  tested,  by  administering  it  to  ten  patients
o  assess  its  understandability  (see  Appendix  1).
The  Positive  and  Negative  Syndrome  Scale  (PANSS)  (Kay,
iszbein,  &  Opler,  1987)  was  used  to  evaluate  the  severity  of
ositive  and  negative  symptoms  and  general  psychopathol-
gy  in  schizophrenia.  Each  item  is  rated  on  a 7-point  Likert
cale  (total  scores  ranging  from  30  to  120).  Higher  scores
ndicate  worse  symptoms.
The  Clinical  Global  Impression-Schizophrenia  Scale  (CGI-
CH)  (Haro  et  al.,  2003) was  designed  to  evaluate  positive,
egative,  depressive,  and  cognitive  symptoms,  and  overall
everity  in  schizophrenia.  Each  item  is  rated  using  a  7-point
ikert  scale  of  intensity  (from  normal  to  among  the  most
everely  ill  patients).
The  Personal  and  Social  Performance  scale  (PSP)  (García-
ortilla  et  al.,  2011)  assessed  patient  functioning  in  socially
seful  activities,  personal  and  social  relationships,  self-
are,  and  disturbing  and  aggressive  behaviors.  Regarding
hese  dimensions,  higher  scores  indicate  worse  level  of
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functioning.  An  overall  global  rating  is  provided,  ranging
from  0  to  100.  Conversely,  higher  scores  indicate  better  level
of  functioning.
The  Global  Assessment  of  Functioning  (GAF)  (American
Psychiatric  Association,  APA,  1987)  considers  psychological,
social,  and  occupational  functioning  on  a  hypothetical  con-
tinuum  of  mental  health-illness,  excluding  impairment  due
to  physical  or  environmental  factors.  The  ratings  range  from
1-10  (severely  impaired)  to  91-100  (superior  functioning).
Statistical  analyses
The  analyses  were  performed  using  SPSS  17.0.  The  two-
tailed  level  of  signiﬁcance  used  was  .05.  Demographic  and
clinical  data  were  evaluated  with  descriptive  statistics,
using  the  mean  and  standard  deviation  for  the  total  sample
and  by  sex.  Sp-SOFI  domain  scores  were  reported  sepa-
rately,  and  as  a  percentile  rank.  Differences  relating  to  the
measurements  were  assessed  using  Chi-square  tests,  Stu-
dent’s  t-tests,  and  ANOVA  (Duncan’s  post-hoc  test).  First  of
all,  in  order  to  determine  the  psychometric  properties  of
the  Sp-SOFI,  the  discrimination  indexes  of  the  items  were
calculated.  The  differential  item  functioning  by  sex  was
estimated  by  logistic  regression  (Gómez-Benito,  Hidalgo,
&  Zumbo,  2013),  and  an  exploratory  factor  analysis  was
carried  out  using  the  correlation  matrix  between  Sp-SOFI
domains.  The  unweighted  least  squares  method  was  used
because  it  showed  the  best  ﬁt  of  the  data  to  the  model.  For
determining  the  dimensionality  the  percentage  of  explained
variance,  the  goodness-of-ﬁt  index  (GFI)  and  the  root-
mean-square  residual  (RMSR)  were  taken  into  account.  The
internal  consistency  of  the  translated  version  was  assessed
using  Cronbach’s  alpha  coefﬁcient.  The  test-retest  reliabil-
ity  of  Sp-SOFI  scores  was  evaluated  over  an  interval  of
6  months  in  the  entire  sample.  The  effect  of  practice  on
retest  performance  on  the  Sp-SOFI  was  determined  by  calcu-
lating  the  effect  sizes  for  changes  in  performance  at  month
6  (Cohen’s  d).  Convergent  validity  was  studied  using  the
correlation  matrix  between  Sp-SOFI  domains  and  PSP  dimen-
sions.  The  canonical  correlation  was  calculated  between
both  sets  of  variables.  On  the  other  hand,  the  multiple  cor-
relation  coefﬁcient  between  the  Sp-SOFI  domains  and  GAF
overall  score  was  determined.  The  expectation  was  that
a  moderate  to  high  r  correlation  would  be  found  for  both
instruments,  as  they  are  functional  outcome  measures.  Also,
known-groups  validity  was  calculated,  as  it  was  by  Kleinman
et  al.  (2009)  in  the  SOFI  development.  Patients  were  strati-
ﬁed  into  two  severity  groups  based  on  median  split  of  PANSS
scores,  and  Sp-SOFI  global  scores  were  compared  by  sever-
ity  level  using  a  t-test.  The  hypothesis  was  that  there  would
be  signiﬁcant  differences  in  functioning  as  measured  by  the
Sp-SOFI  when  patients  with  more  symptoms  as  measured
by  the  PANSS  were  compared  to  patients  with  fewer  symp-
toms  (Kleinman  et  al.,  2009).  To  determine  discriminant
validity,  patients  were  classiﬁed  into  four  groups  based  on
CGI  scores  of  the  Positive,  Negative,  Cognitive,  and  Overall
Severity  Symptoms  Scales:  doubtful  (1-  2),  mild  (3),  mod-
erate  (4),  or  severe  (≥  5)  (García-Portilla  et  al.,  2013).  To
identify  statistically  signiﬁcant  differences  in  the  Sp-SOFI
domain  scores  according  to  severity  groups  in  each  CGI  scale,
an  ANOVA  with  Duncan’s  post-hoc  test  was  calculated.  The
r
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xpectation  was  that  less  severely  ill  patients  would  have
igher  Sp-SOFI  scores.
esults
emographic  and  clinical  patient  characteristics
able  1  shows  the  demographic  and  clinical  patient  charac-
eristics  (total  sample  and  by  sex).  No  signiﬁcant  differences
ere  found  according  to  sex  except  for  marital  status
2 =  13.3;  p  =  .004)  and  work  status  ( 2 =  7;  p  =  .029).
Table  2  shows  the  characteristics  of  the  Sp-SOFI  scores.
tatistically  signiﬁcant  differences  were  found  in  all  domains
ccording  to  sex,  except  for  number  2  (instrumental  activ-
ties  of  daily  living),  with  females  scoring  higher.  Table  2
lso  presents  percentile  ranks  of  the  Sp-SOFI  for  the  total
ample  and  by  sex.  It  is  worth  noting  here  that  lower  scores
re  indicative  of  poorer  adjustment.  The  Sp-SOFI  score  cor-
esponding  to  the  25th  percentile  was  44.2.  Scores  ranging
etween  62.5  and  77  corresponded  to  the  50th  and  75th
ercentiles.
tem  analysis  of  the  Sp-SOFI
he  Sp-SOFI  was  composed  of  items  with  discrimination
ndexes  ranging  from  .21  to  .77.  No  items  presented  dif-
erential  item  functioning  (DIF)  by  sex  (p  <  .01;  R2 <  .035).
able  3  shows  the  correlation  matrix  between  Sp-SOFI
omain  scores,  which  were  positively  and  strongly  corre-
ated.
The  results  obtained  in  the  exploratory  factor  anal-
sis  showed  Kaiser-Meyer-Olkin  (KMO)  indexes  above  .80
Table  4),  as  well  as  a  statistically  signiﬁcant  Bartlett’s
phericity  index  (p  <  .001).  All  the  factor  loadings  were  in
he  range  of  .72  to  .92.  As  can  be  seen  in  Table  4,  the  GFI
as  above  .95,  the  RMSR  was  under  .08,  and  the  percentage
f  variance  explained  by  the  factor  analysis  is  76.22%.
nternal  consistency
p-SOFI  reliability  judged  by  internal  consistency
Cronbach’s  alpha)  was  .93.  Test-retest  stability  between
p-SOFI  domains  was  also  adequate  with  a Pearson  correla-
ion  of  .80  to  .82  (p  <  .001)  after  6  months.  For  the  Sp-SOFI
otal  score,  r  was  .87  (p  <  .001).  Practice  effects  on  the
p-SOFI  were  very  small  (Cohen’s  d  =  0.09).
onvergent  validity
he  Pearson  correlation  matrix  between  Sp-SOFI  domains
nd  PSP  dimensions  are  shown  in  Table  5.  All  the  scores
ere  strongly  and  negatively  correlated  (p  <  .001).  Note
hat  higher  scores  in  PSP  dimensions  mean  worse  level  of
unctioning.  Canonical  correlation  between  the  two  sets  of
ariables  is  shown  in  Table  6.  As  can  be  seen,  the  canonical
orrelation  was  .83.  The  Sp-SOFI  domain  with  the  highest
elevance  was  ‘‘living  situation’’  (domain  1).  The  multiple
orrelation  coefﬁcient  between  Sp-SOFI  domains  and  GAF
otal  score  was  .84,  so  71.22%  of  GAF  total  variance  was
xplained  by  Sp-SOFI  domains.
62  S.  Al-Halabí  et  al.
Table  1  Demographic  and  clinical  characteristics  of  the  total  sample  and  by  sex.
Total  sample
n  =  155
Male
n  =  102
Female
n  =  53
Age  40.27  (10.9)  41.2  (11.7)  47  (11)
Marital status  [n  (%)a]
Single  118  (76.1%)  86  (55.4%)  32  (20.6%)
Married/Cohabiting  24  (15.4%)  9  (5.8%)  15  (9.6%)
Separated/Divorced  13  (8.3%)  7  (4.5%)  5  (3.2%)
Widowed 1  (0.6%)  0  1  (0.6%)
Educational level  [n  (%)a]
Primary  school 51  (32.9%) 36  (23.2%) 15  (9.6%)
Secondary school 62  (20.6%) 43  (27.7%) 19  (12.2%)
University 16  (10.3%) 8  (5.1%) 8  (5.1%)
Work status  [n  (%)a]
Working  21  (13.5%)  13  (8.3%)  8  (5.1%)
Not workingb 90  (58%)  53  (34.1%)  37  (23.8%)
Permanently disabled  (mental  illness)  44  (28.3%)  36  (23.2%)  8  (5.1%)
Clinical measures  [mean  (SD)]
PANSS  Total  Score  66.0  (22.4)  68.1  (20.2)  62.0  (26)
PANSS-Positive  Scale  14.8  (7.4)  15.4  (7.3)  13.8  (7.6)
PANSS-Negative  Scale  18.7  (7.3)  19.3  (6.7)  17.4  (8.3)
PANSS-General  Scale  32.4  (11.2)  33.3  (10.5)  30.7(12.4)
CGI-SCH Global  Severity  3.4  (1.1)  3.5  (1)  3.2  (1.1)
CGI-SCH Positive  2.7  (1.5)  2.9  (1.5)  2.4  (1.5)
CGI-SCH Negative  3.0  (1.3)  3.1  (1.3)  2.8  (1.4)
CGI-SCH Depressive  2.1  (1.1)  2.1(1)  2.3  (1.2)
CGI-SCH Cognitive 2.5  (1.2)  2.5  (1.2)  2.3  (1.2)
Functional outcome  measures  [mean  (SD)]
PSP total  score 57.6  (20.7)  54.9  (20.5)  62.4  (20.3)
GAF 60  (15.4)  58.57  (14.8)  62.4  (16.3)
Note. SD = standard deviation.
a Due to information not available, percentages may not add up to exactly 100%.
b Not working included: permanent and temporary disability for health conditions other than mental disorder, retired, and unemployed.
Table  2  Distribution  of  Sp-SOFI  scores  for  total  sample  and  by  sex.
Total  sample  Male  Female  t  p
Sp-SOFI  domains  [mean(SD)]
1. Living  situation  65.4  (21.5)  62.6  (20.6)  70  (22.3)  −2.06  .040*
2.  IADL  61.6  (22.2)  59.1  (21.4)  66.3  (23.3)  −1.93  0.055
3. Productive  activities  51.8  (30.7)  46.5  (31.3)  61.8  (27.4)  −2.98  .003*
4.  Social  functioning  60  (22.6)  56.5  (21.8)  66  (22.9)  −2.50  .013*
Sp-SOFI  Total  Score  59.6  (21.1)  56.2  (20.6)  65.9  (20.8)  −2.74  .007**
25th  Percentile  44.2  42.5  54.6
50th Percentile  62.5  57.6  70.7
75th Percentile  77  72.6  81.4
* p<.05;
**
m
s
s
d
f
t
dp<.01
On  the  other  hand,  known-groups  validity  was  deter-
ined  separately  for  all  PANSS  subscales  (median  Positivecale  =  13;  median  Negative  scale  =  18;  median  General
cale  =  30.5).  Mean  Sp-SOFI  total  scores  were  signiﬁcantly
ifferent  for  the  PANSS-Positive  based  groups  (p=.007)  and
or  each  domain  (p  <  .005),  except  for  domain  3  (produc-
a
w
b
cive  activities).  Groups  based  on  the  PANSS-Negative  scale
emonstrated  statistically  signiﬁcant  mean  differences  for
ll  the  Sp-SOFI  domains  and  total  score  (all  p  <  .001).  Like-
ise,  all  Sp-SOFI  scores  also  were  signiﬁcantly  different
etween  high  and  low  scores  on  the  PANSS-General  Psy-
hopathology  scale  (all  p  <  .001).
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Table  3  Correlation  matrix  among  Sp-SOFI  domain  scores.
Living  Situation
(D1)
D2  D3
IADL  (D2)  .79*
Productive
activities  (D3)
.71* .72*
Social  functioning
(D4)
.65* .68* .50*
* p<.001
Table  4  Factor  analysis  of  the  SP-SOFI  domain  scores.
Factor  I
1.  Living  situation  .89
2. IADL  .92
3. Productive  activities  .77
4. Social  functioning  .71
Explained  variance  76.22%
GFI .99
RMSR (SE)  .02  (.08)
Cronbach’s  alpha  .93
Table  6  Canonical  correlation  between  the  Sp-SOFI
domains  and  PSP  dimensions.
Standardized
canonical
coefﬁcients
Canonical
correlation
(R)
Sp-SOFI  domains
1.  Living  situation  −.54
2.  IADL  −.19
3.  Productive  activities  −.14
4.  Social  functioning  −.23  .83
PSP dimensions
a.  Self-care .37
b.  Personal  and  social
relationships
.24
c.  Socially  useful
activities
.49
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expected,  correlations  between  Sp-SOFI  domains  and  PSPNote. GFI = Goodness of Fit Index; RMSR = Root-Mean-Square
Residual; SE = Standard Error.
Discriminant  validity
All  Sp-SOFI  measures  demonstrate  an  ability  to  discriminate
among  patients  with  doubtful  (CGI  =  1--2),  mild  (CGI  =  3),
moderate  (CGI  =  4),  and  severe  (CGI≥5) schizophrenia  disor-
der  according  to  CGI-SCH  Positive,  Negative,  Cognitive,  and
Overall  Severity  Symptoms  scales  (all  p  <  .001).  As  expected,
less  severe  patients  have  higher  Sp-SOFI  scores.  Table  7
shows  the  mean  Sp-SOFI  domains  and  total  scores  for  each
severity  group  on  each  CGI-SCH  scale.
Discussion
This  paper  reports  the  ﬁrst  validation  of  the  Schizophre-
nia  Objective  Functioning  Instrument  (SOFI)  in  a  sample  of
patients  with  schizophrenia  receiving  standard  maintenance
treatment  in  Spain.  We  found  good  psychometric  properties,
which  conﬁrm  the  Sp-SOFI  as  a  reliable  and  valid  instrument
for  assessing  functioning  in  daily  clinical  practice.
d
t
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Table  5  Correlation  matrix  among  Sp-SOFI  domains  and  PSP  dime
Self-care  Personal  and
relationships
Sp-SOFI  domains
1. Living  situation  −.68* −.69*
2.  IADL  −.60* −.65*
3.  Productive  activities  −.58* −.62*
4.  Social  functioning  −.45* −.59*
* p<.001d.  Disturbing  and
aggressive  behaviors
.05
All  the  Sp-SOFI  items  have  shown  good  psychomet-
ic  properties,  including  adequate  discrimination  indexes
Mun˜iz,  Fidalgo,  García-Cueto,  Martínez,  &  Moreno,  2005)
nd  no  differential  item  functioning  by  sex  (Gómez-Benito
t  al.,  2013).  Exploratory  factor  analysis  showed  that  the
our  domains  have  an  essentially  one-dimensional  struc-
ure  (Kline,  2005).  In  addition,  the  high  internal  consistency
˛  =  .93)  of  the  Sp-SOFI  permits  the  deﬁnition  and  assess-
ent  of  a  global  factor  that  groups  these  four  domains.
hese  results  add  new  evidence  of  validity  to  the  previous
eport  (Kleinman  et  al.,  2009).
Test-retest  reliability  was  good  (from  .80  to  .82)  for  all
he  Sp-SOFI  domains,  especially  in  view  of  the  fact  that  the
nterval  period  in  our  study  was  only  6  months.  With  respect
o  the  impact  of  practice  on  Sp-SOFI  performance,  a  very
mall  effect  size  was  found  in  our  patients.  This  data  are
imilar  to  those  reported  by  Kleinman  et  al.  (2009).  In  this
ense  and  regarding  to  the  reliability,  we  believe  now  that
lso  would  have  been  interesting  to  study  the  inter-rater
eliability,  due  to  the  role  of  judgment  in  the  SOFI  scoring.
his  issue  would  be  an  area  for  further  research.
Evidence  supporting  convergent  validity  was  good.  Asimensions  were  high  due  to  the  conceptual  overlap  of
he  instruments.  As  previously  reported  by  Kleinman  et  al.
2009),  the  PSP  measures  patient  functioning  in  several
nsions.
PSP  dimensions
 social Socially  useful
activities
Disturbing  and
aggressive  behaviors
−.71* −.34*
−.69* −.37*
−.56* −.21*
−.68* −.34*
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Table  7  Sp-SOFI  scores  according  to  schizophrenia  severity  determined  by  CGI-SCH  scores  (ANOVA).
Sp-SOFI  Domain  Scores  CGI-SCH  Positive  scale
Doubtful
(n  =  80)
Mild
(n  =  28)
Moderate
(n  =  26)
Severe
(n  =  21)
F1
Living  situation 73.07 66.14  59.96  41.62  16.25*,a
IADL  69.30 62.46 55.15 39.24 13.76*,b
Productive  activities 59.16 54.14 45.54 28.38 6.65*,c
Social  functioning  67.24  62.79  49.77  41.00  11.52*,d
Sp-SOFI  Total  Score  67.11  61.38  52.61  37.56  15.29*,e
CGI-SCH  Negative  scale
Doubtful
(n  =  23)
Mild
(n  =  30)
Moderate
(n  =  45)
Severe
(n  =  57)
Living  situation 77.11 68.38 54.05  46.25  20.80*,f
IADL  72.05 65.98 53.62  39.00  19.39*,g
Productive  activities 65.16 57.31 34.12 32.38  12.93*,h
Social  functioning 71.32 61.47 53.55 38.42 16.78*,i
Sp-SOFI  Total  Score 71.34 63.28 48.83 39.01  23.54*,j
CGI-SCH  Cognitive  scale
Doubtful
(n  =  83)
Mild
(n  =  29)
Moderate
(n  =  30)
Severe
(n  =  9)
Living  situation  71.19  64.41  58.33  41.67  7.42*,k
IADL  67.30  61.72  54.03  36.78  7.34*,l
Productive  activities  57.52  51.41  43.53  35.33  2.63*,m
Social  functioning  67.27  60.17  47.30  32.56  12.45*,n
Sp-SOFI  Total  Score  65.73  59.43  50.80  36.58  8.57*,o
CGI-SCH  Depressive  scale
Doubtful
(n  =  94)
Mild
(n  =  39)
Moderate
(n  =  18)
Severe
(n  =  3)
Living  situation  68.72  62.99  51.72  75.00  3.67**,p
IADL  64.97  60.09  46.28  65.33  3.81
Productive
activities
56.42 45.58  38.17  60.33  2.53
Social functioning  62.87  63.35  39.33  42.00  7.10*,q
Sp-SOFI  Total
Score
63.14  58.00  43.88  60.67  4.50
CGI-SCH  Overall  Severity  scale
Doubtful
(n  =  34)
Mild
(n  =  47)
Moderate
(n  =  47)
Severe
(n  =  27)
Living  situation  80.71  73.35  59.62  41.11  33.99*,r
IADL  76.68  68.67  54.83  41.78  21.45*,s
Productive
activities
69.65  61.61  42.72  26.00  16.84*,t
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Table  7  (Continued  )
CGI-SCH  Overall  Severity  scale
Doubtful
(n  =  34)
Mild
(n  =  47)
Moderate
(n  =  47)
Severe
(n  =  27)
Social
functioning
73.50  68.03  51.94  43.04  16.93*,u
Sp-SOFI  Total
Score
75.13 67.91 52.28 36.92 33.18*,v
Note.
* p<.05;
** p<.01.
1 Duncan’s post-hoc test.
a Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
b Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
c Severely ill patients differed from moderately, mildly, and doubtfully ill patients.
d Severely ill patients differed from moderately, mildly, and doubtfully ill patients.
e Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
f Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Mildly ill differed from doubtfully ill.
g Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
h Severely and moderately ill patients differed from mildly and doubtfully ill patients.
i Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately and mildly ill differed from doubtfully
ill.
j Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
k Severely ill patients differed from moderately, mildly, and doubtfully ill patients.
l Severely ill patients differed from moderately, mildly, and doubtfully ill patients.
m Severely ill patients differed from doubtfully ill patients.
n Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
o Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
p Severely ill patients differed from doubtfully ill patients.
q Severely and moderately ill patients differed from mildly and doubtfully ill patients.
r Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
s Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
t Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
ill.
u Severely and moderately ill patients differed from mildly and doubtfully ill patients.
v Severely ill patients differed from moderately, mildly, and doubtfully ill patients. Moderately ill differed from mildly and doubtfully
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areas  was  similar  to  the  SOFI.  In  fact,  the  canonical  cor-
relation  coefﬁcient  between  the  two  sets  of  variables  was
0.83,  which  indicates  that  convergent  validity  of  the  Sp-
SOFI  is  excellent  according  to  the  model  of  EFPA  for  the
evaluation  of  the  quality  of  tests  (Evers  et  al.,  2013).  Addi-
tionally,  the  multiple  correlation  coefﬁcient  between  the
Sp-SOFI  domains  scores  and  the  total  score  on  the  GAF  was,
as  expected,  positive  and  strong  in  magnitude,  thus  con-
ﬁrming  the  hypothesis  that  the  Sp-SOFI  measures  functional
outcomes.Continuing  with  the  construct  validity,  we  found  very
similar  data  to  those  reported  by  Kleinman  et  al.  (2009)
regarding  the  SOFI  ability  to  differentiate  between  patients
with  a  high  and  low  degree  of  psychopathology.  Patients
h
t
b
rith  more  impairment  in  clinical  symptoms  on  all  PANSS
cales  (positive,  negative,  and  general)  were  rated  as  hav-
ng  worse  functional  outcomes  using  the  Sp-SOFI.  In  this
egard,  we  think  that  these  data  do  not  demonstrate  the
bility  of  the  SOFI  to  measure  the  link  between  cognition
nd  functioning--as  designed  by  Kleinman  et  al.,  2009--but
he  relationship  between  symptomatic  domains  and  cogni-
ive  domains  is  strong  (Lin  et  al.,  2013).  Negative  symptoms
re  found  to  have  the  strongest  relationship  with  cognition;
hey  produce  the  greatest  impact  on  functioning,  life-style
abits,  and  somatic  health  of  the  individuals  manifesting
hem.  Numerous  studies  have  shown  a  positive  correlation
etween  the  seriousness  of  negative  symptoms  and  dete-
ioration  in  patient  social,  family,  and  work  functioning
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García-Portilla  &  Bobes,  2013).  Nevertheless,  a  weak  asso-
iation  was  also  noted  with  positive  symptoms  such  as  reality
istortion,  as  well  as  depressive  symptoms  with  cognition.
he  relationship  among  cognition,  clinical  symptoms,  and
unctional  outcome  is  complex  and  it  is  important  to  take  all
hese  factors  into  account  simultaneously  while  investigat-
ng  their  interactions  (Lin  et  al.,  2013).  In  this  regard,  Green
nd  Harvey  (2014)  have  suggested  that  functional  capac-
ty  and  cognitive  skills  may  both  reﬂect  a  broader  common
rait  called  ‘‘ability.’’  Several  studies  with  different  samples
ave  suggested  that  there  may  be  one  ability  trait  that  cuts
cross  tasks  labeled  ‘‘neurocognitive’’  and  those  designated
‘functional’’  (Green  &  Harvey,  2014).
On  the  other  hand,  regarding  discriminant  validity,  the
p-SOFI  is  able  to  discriminate  among  degrees  of  mental  dis-
rder  severity  in  the  expected  direction.  In  general  terms,
atients  with  severe  mental  disorders  obtained  signiﬁcantly
ower  scores  than  the  other  three  groups,  while  patients
ith  mild  mental  disorders  obtained  signiﬁcantly  higher
cores  than  the  other  groups  (it  should  be  remembered  that
igher  Sp-SOFI  scores  indicate  better  functioning).  In  addi-
ion,  severely  ill  patients  generally  scored  signiﬁcantly  lower
han  moderately  and  mildly  ill  patients  and,  in  turn,  moder-
tely  ill  patients  scored  signiﬁcantly  lower  than  those  mildly
r  doubtfully  ill.  This  score  gradient  is  especially  remark-
ble  for  the  CGI-SCH-Cognition  scale,  given  the  link  between
ognition  and  functional  outcomes  that  SOFI  aims  to  make,
nd  has  also  been  found  for  all  CGI-SCH  scales,  except  the
nstrumental  activities  of  daily  living  (IADL)  and  produc-
ive  activities  of  the  CGI-SCH-Depressive  scale.  This  may  be
xplained  by  the  fact  that  the  sample  distribution  is  very
rregular  in  CGI-SCH-Depressive  scores.  In  fact,  ninety-four
atients  scored  doubtful,  while  only  three  scored  severe.
his  does  not  allow  any  conclusions  in  this  respect.
Regarding  the  clinical  characteristics  of  our  patients  sam-
le,  PANSS  scores  were  reﬂective  of  a  stable  non-acute
opulation  with  a  mean  score  of  14.7  (SD  =  7.4)  on  the  Pos-
tive  scale  and  18.7  (SD  =  7.3)  on  the  Negative  scale.  This
eans  values  were  similar  to  those  reported  by  other  stud-
es  in  patients  with  schizophrenia,  such  as  17.1  (SD  =  5.8)  and
8.7  (SD  =  6.5)  reported  by  Kleinman  et  al.  (2009),  and  18.2
SD  =  7.7)  and  2.0  (SD  =  9.1)  reported  by  Haro  et  al.  (2003),
n  Positive  and  Negative  scales  respectively.
Finally,  there  is  the  conversion  of  the  Sp-SOFI  total  scores
o  principal  percentiles  as  established  in  order  to  compare
n  individual’s  position  relative  to  the  distribution  of  the
ample  as  a  whole.  In  our  opinion,  patients  in  the  ≤25th
ercentile  should  be  considered  the  at-risk  group,  in  the
ense  that  the  clinician  should  comprehensively  take  into
ccount  the  problems  associated  with  a  poor  functioning.  In
his  regard,  it  should  be  noted  that  the  female  subsample
ad  higher  scores  (better  functioning)  on  the  Sp-SOFI  than
ales.  Similarly,  both  PANSS  and  CGI-SCH  scores  are  higher  in
ales,  meaning  greater  symptom  severity.  Likewise,  scores
n  functional  outcome  measures  (PSP  and  GAF)  were  higher
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better  functioning)  in  the  female  group.  This  means  that
he  scores  found  on  the  Sp-SOFI  are  consistent  with  the  other
easures  and  adjusted  to  the  clinical  characteristics  of  the
ample.
The  external  validity  of  this  study  can  be  considered
ood  since  the  patients  included  are  similar  to  stable  out-
atients  who  are  on  treatment  for  schizophrenia  in  daily
linical  practice  throughout  Spain.  The  study  inclusion  and
xclusion  criteria  were  non-restrictive  and  patients  from  ﬁve
ifferent  cities  in  Spain  were  included  in  the  study.  How-
ver,  as  Kleinman  et  al.  (2009)  reported,  further  research
s  needed  to  examine  measurement  qualities  in  different
nd  larger  schizophrenia  samples.  This  sample  may  not  be
eneralizable  to  unstable  patients  enrolled  in  clinical  tri-
ls.  Additional  research  on  more  heterogeneous  samples  of
chizophrenia  patients  is  required  to  draw  conclusions  about
sychometric  performance  across  a  broader  spectrum  of  dis-
ase  severity  (Kleinman  et  al.,  2009).
In  addition  to  all  that  has  been  already  said,  three  lim-
tations  should  be  taken  into  account  when  interpreting
his  study.  First,  although  the  CGI-SCH  Cognition  Scale  was
sed  as  a  measure  of  cognition,  there  is  no  performance
ata  from  a  cognitive  battery.  In  this  sense,  it  would  have
een  interesting  to  use  the  Brief  Assessment  of  Cognition  in
chizophrenia  (BACS),  as  was  done  by  Kleinman  et  al.  (2009)
n  their  study.  Second,  is  the  lack  of  a  control  group.  Fur-
her  studies  are  needed  to  demonstrate  the  sensitivity  of
he  Sp-SOFI  to  changes  related  to  an  intervention.  Third,
he  sample  size  of  this  study  was  quite  modest.  From  psy-
hometric  and  statistical  perspective,  larger  samples  would
e  necessary  to  obtain  stronger  and  more  stable  conclusions
bout  the  SOFI.  In  this  sense,  it  would  be  advisable  to  per-
orm  replication  studies,  as  well  as  extensions  to  a  broader
ange  of  samples  of  patients  with  schizophrenia.
In  summary,  in  light  of  the  global  data,  we  are  able  to
emonstrate  that  the  Spanish  version  of  the  SOFI  (Sp-SOFI)  is
eliable  and  valid  for  measuring  functioning  in  patients  with
chizophrenic  disorders.  Also,  new  evidence  about  the  valid-
ty  of  the  instrument  was  provided.  As  a  performance-based,
linician-rated  instrument,  the  Sp-SOFI  seems  to  be  appro-
riate  for  use  in  clinical  practice  as  a means  of  monitoring
unctioning  in  this  population.
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Appendix 1. Spanish version of  Schizophrenia Objective Functioning Instrument (Sp-SOFI).
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